Actively Recruiting
Chemotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma
Led by University of Louisville · Updated on 2025-10-29
20
Participants Needed
1
Research Sites
478 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Compare the efficacy and tolerability of IRE in combination with either FOLFIRINOX or gemcitabine in patients with locally advanced pancreatic cancer.
CONDITIONS
Official Title
Chemotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- 18 years of age or older
- Diagnosed with stage III pancreatic cancer
- Tumor is measurable
- Glomerular filtration rate (GFR) greater than specified mL/min/1.73m2
- Willing and able to follow study protocol requirements
- AST/ALT liver enzymes elevated more than 3 times the upper limit of normal
- Stable post-operative recovery as defined by the surgeon
You will not qualify if you...
- Currently participating in another cancer treatment clinical trial
- Pregnant or breastfeeding
- Have a cardiac pacemaker or ICD that cannot be deactivated during IRE
- Have non-removable metal implants within 1 cm of the target tumor
- Had a heart attack within 3 months before enrollment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Louisville
Louisville, Kentucky, United States, 40202
Actively Recruiting
Research Team
R
Robert Martin, MD, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here